The capital will be used to support rapid expansion of some of Verily's leading commercial businesses. These include Baseline, an end-to-end ecosystem designed to make clinical research more efficient; and Verily Health Platforms, which supports population health, clinical care delivery and chronic disease management through programs like Healthy at Work, Onduo and Coefficient . The company will also progress several of its life sciences programs across surgery, pathology and immunology.

Launched in 2015, Verily is a subsidiary of Alphabet focused on life sciences and healthcare. Our mission is to make the world's health data useful so that people enjoy healthier lives. Verily develops tools and devices to collect, organize and activate health data, and creates interventions to prevent and manage disease. We partner with leading life sciences, medical device and government organizations, using deep hardware, software, scientific, and healthcare expertise to enable faster development, meaningful advances, and deployment at scale. Learn more at www.verily.com.